NCT04243616View on ClinicalTrials.gov

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

August 11, 2025

Study Completion Date

August 12, 2030

Conditions
Invasive Breast Cancer
Interventions
DRUG

Cemiplimab

350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)

DRUG

Paclitaxel

80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)

DRUG

Carboplatin (not mandatory)

Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)

DRUG

Doxorubicin

60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)

DRUG

Cyclophosphamide

600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)

Trial Locations (1)

53226

Froedtert Hospital & Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT04243616 - Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter